741 related articles for article (PubMed ID: 24658273)
1. Targeting Bruton's tyrosine kinase in B cell malignancies.
Hendriks RW; Yuvaraj S; Kil LP
Nat Rev Cancer; 2014 Apr; 14(4):219-32. PubMed ID: 24658273
[TBL] [Abstract][Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
4. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
Ponader S; Burger JA
J Clin Oncol; 2014 Jun; 32(17):1830-9. PubMed ID: 24778403
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Alinari L; Quinion C; Blum KA
Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
[TBL] [Abstract][Full Text] [Related]
7. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
da Cunha-Bang C; Niemann CU
Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
Lucas F; Woyach JA
Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
[TBL] [Abstract][Full Text] [Related]
9. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.
Gu D; Tang H; Wu J; Li J; Miao Y
J Hematol Oncol; 2021 Mar; 14(1):40. PubMed ID: 33676527
[TBL] [Abstract][Full Text] [Related]
10. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Seiler T; Dreyling M
Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
[TBL] [Abstract][Full Text] [Related]
12. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib and indolent B-cell lymphomas.
Akinleye A; Furqan M; Adekunle O
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):253-60. PubMed ID: 24445187
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.
Burger JA
Curr Hematol Malig Rep; 2014 Mar; 9(1):44-9. PubMed ID: 24357428
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
Davids MS; Brown JR
Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
[TBL] [Abstract][Full Text] [Related]
17. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Valla K; Flowers CR; Koff JL
Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
[TBL] [Abstract][Full Text] [Related]
18. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
19. The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C; Xanthopoulos C; Kostareli E
Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
[TBL] [Abstract][Full Text] [Related]
20. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
Winer ES; Ingham RR; Castillo JJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):355-61. PubMed ID: 22300471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]